Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0F3JT
|
||||
| Former ID |
DAP000287
|
||||
| Drug Name |
Mecasermin
|
||||
| Synonyms |
Increlex (TN)
|
||||
| Indication | Growth failure [ICD10:R62.8] | Approved | [1], [2] | ||
| Therapeutic Class |
Immunomodulatory Agents
|
||||
| Formula |
C331H518N94O101S7
|
||||
| CAS Number |
CAS 68562-41-4
|
||||
| SuperDrug ATC ID |
H01AC03
|
||||
| Target and Pathway | |||||
| Target(s) | Insulin-like growth factor I receptor | Target Info | Inhibitor | [3], [4], [5], [6] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| FoxO signaling pathway | |||||
| Oocyte meiosis | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| AMPK signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Long-term depression | |||||
| Ovarian steroidogenesis | |||||
| Progesterone-mediated oocyte maturation | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Proteoglycans in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| PANTHER Pathway | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | ||||
| Insulin/IGF pathway-protein kinase B signaling cascade | |||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
| SHP2 signaling | |||||
| IGF1 pathway | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Integrins in angiogenesis | |||||
| Stabilization and expansion of the E-cadherin adherens junction | |||||
| Reactome | IRS-related events triggered by IGF1R | ||||
| SHC-related events triggered by IGF1R | |||||
| WikiPathways | Senescence and Autophagy in Cancer | ||||
| Insulin Signaling | |||||
| Endochondral Ossification | |||||
| Focal Adhesion | |||||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||||
| Apoptosis | |||||
| Signaling Pathways in Glioblastoma | |||||
| TSH signaling pathway | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| References | |||||
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 2 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | ||||
| REF 3 | One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. Arthritis Rheum. 2003 May;48(5):1302-14. | ||||
| REF 4 | IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45. Epub 2003 Jul 5. | ||||
| REF 5 | Insulin-like growth factor I receptor gene structure. J Biol Chem. 1992 May 25;267(15):10759-63. | ||||
| REF 6 | Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1113-20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.